

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Molnupiravir

December 17, 2024

Therapeutic category

Anti-virus agents

Non-proprietary name

Molnupiravir

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision
(N/A)	<p data-bbox="1133 261 1536 288"><u>8. IMPORTANT PRECAUTIONS</u></p> <p data-bbox="1162 309 2002 435"><u>The necessity of administering this drug to women of childbearing potential should be carefully considered. If administration is deemed necessary, attention should be paid to the following points.</u></p> <p data-bbox="1189 456 2002 582"><u>Prior to administering this drug, the absence of pregnancy and the absence of the possibility of pregnancy should be confirmed through sufficient patient interviews.</u></p> <p data-bbox="1189 603 2002 678"><u>The following should be explained to patients before starting administration of this drug:</u></p> <ul data-bbox="1189 699 2002 1013" style="list-style-type: none"><li data-bbox="1189 699 2002 774"><u>•This drug can cause foetal harm when administered to a pregnant woman.</u><li data-bbox="1189 794 2002 869"><u>•If pregnancy is detected or suspected during administration of this drug, this drug should be discontinued immediately.</u><li data-bbox="1189 890 2002 1013"><u>•If pregnancy is detected or suspected during administration of this drug or within 4 days after the last administration of this drug, a physician, pharmacist, etc. should be consulted promptly.</u>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.